Please login to the form below
sipuleucel-T
This page shows the latest sipuleucel-T news and features for those working in and with pharma, biotech and healthcare.
Sanofi forges $1.5bn cancer partnership with BioNTech
Earlier this year, BioNTech also forged a $360m alliance with Eli Lilly for the discovery of novel tumour targets and the development of T cell receptor (TCR) therapies for multiple cancer ... s cancer vaccine Provenge (sipuleucel-T).
Latest news
-
Dendreon wins IQWiG U-turn for its immunotherapy Provenge
Provenge (sipuleucel-T) was approved in Europe in 2013 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy.
-
BMS signs $975m deal for Bavarian Nordic cancer vaccine
Unlike Dendreon's prostate cancer vaccine Provenge (sipuleucel-T), which is being acquired by Valeant despite a lacklustre showing in the market, Prostvac is ready-to-use and does not require
-
Good NICE news for Pfizer, but Dendreon drug rejected
NICE has given a final recommendation to Pfizer's new kidney cancer pill Inlyta (axitinib) - but has rejected Dendreon's prostate cancer treatment Provenge (sipuleucel-T). ... Commenting on the Provenge decision, Professor Longson said: “Unfortunately
-
Valeant and Shire said to be evaluating potential Salix bids
in the running to acquire Provenge (sipuleucel-T) and expects to close the deal by the end of the month. ... Dendreon has struggled with low sales of its Provenge (sipuleucel-T) prostate cancer vaccine since it was launched in 2010 - thanks to a hefty
-
Valeant lead bidder for troubled Dendreon
Valeant has made an initial bid of $296m in cash for Seattle-based Dendreon, which filed for bankruptcy at the end of 2014 as sales of its lead product Provenge ... T) for prostate cancer fell short of expectations.
More from news
Approximately 2 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
Medius Deal Watch table for February 2015
Corporate acquisition. 400. Dendreon/ Valeant Pharmaceuticals. PROVENGE (sipuleucel-T) and other assets - prostate cancer.
-
Pharma deals in February 2015
This month saw the deadline, highlighted in January's Deal Watch, for Valeant to acquire Dendreon, and more specifically the dendritic cell, prostate cancer vaccine Provenge (sipuleucel-T), come and go. ... NICE has concluded that the price is “too
-
Pharma deals during January 2015
The lead candidate CM-CS1 is phase 1 ready and the acquisition brings access to 2 CAR T-cell programmes in preclinical development plus the allogeneic T-cell platform allowing the ... Staying with immuno-oncology, an acquisition in the making is the
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Dendreon appoints new R&D lead
The appointment comes at a time when the Californian biopharma drives to expand the use of Provenge (sipuleucel-T).
-
Lindsay Rocco to lead corporate communications at Dendreon
The US biotech, which markets prostate cancer vaccine Provenge (sipuleucel-T), said Rocco will be responsible for all communications functions of the company, reporting directly to chair, president and CEO John
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Genetic Digital
Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
